Concurrent administration of amiodarone and atenolol in the treatment of coronary artery disease complicated with arrhythmia, and its effect on serum levels of CD40L, TNF-α and IL-6

• Published in: Tropical journal of pharmaceutical research Vol. 21; no. 5; pp. 1073 - 1078
• Main Authors: Li, Dejin, Tang, Chengyue, Xu, Liqiong, Jin, Xin, Wu, Jianli, Ran, Jiuju, Chen, Anfang
• Format: Journal Article
• Language: English
• Published: 18.06.2022
• ISSN: 1596-5996; 1596-9827
• DOI: 10.4314/tjpr.v21i5.23

Purpose: To investigate the efficacy of the combination of amiodarone and atenolol in the treatment of patients with coronary artery disease (CAD) complicated with arrhythmia, and its effect on serum levels of CD-40L, TNF-α and IL-6.Methods: One hundred and twenty CAD patients with arrhythmia on admission in The First People'sHospital of Shuangliu District Chengdu, China were assigned to groups A and B, each having 60 patients. Amiodarone was administered to all the patients, while atenolol was additionally given to patients in group A. Levels of heart function indicators, inflammatory factors, blood pressure, heart rate, adverse reaction rate (ARR) and overall efficacy were evaluated for the two groups.Results: There were significantly improved levels of heart function indicators, and lower levels of CD40L, TNF-α and IL-6 in group A, when compared with group B (p < 0.001). Moreover, treatment effectiveness was higher in group A than in group B (p < 0.05). However, there was no significant difference (p > 0.05) in ARR between groups A and B.Conclusion: The combined use of amiodarone and atenolol improves heart function indicators in patients with CAD and arrhythmia, reduces the levels of inflammatory factors, normalizes blood pressure and heart rate, and lowers ARR. However, further clinical trials on this combined therapy are required prior to its use in clinical practice.